Analyzing Alkermes (NASDAQ:ALKS) & ULURU (OTCMKTS:ULUR)
Analyzing Alkermes (NASDAQ:ALKS) & ULURU (OTCMKTS:ULUR)
ULURU (OTCMKTS:ULUR – Get Rating) and Alkermes (NASDAQ:ALKS – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.
烏魯魯(OTCMKTS：ULUR-GET Rating)和艾爾建(納斯達克：ALKS-GET Rating)都是醫療公司，但哪一家更好？我們將根據這兩家公司分析師推薦的風險、股息、盈利能力、收益、估值和機構持股的強弱進行比較。
Risk & Volatility
風險與波動性
ULURU has a beta of -1.97, meaning that its share price is 297% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
烏魯魯的貝塔係數為-1.97，這意味着其股價的波動性比標準普爾500指數低297%。相比之下，Alkermes的貝塔係數為0.61，這意味着其股價的波動性比標準普爾500指數低39%。
Analyst Recommendations
分析師建議
This is a summary of recent ratings for ULURU and Alkermes, as reported by MarketBeat.com.
這是MarketBeat.com報道的烏魯魯和阿爾克姆斯最近的評級摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ULURU | 0 | 0 | 0 | 0 | N/A |
| Alkermes | 0 | 4 | 4 | 0 | 2.50 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 烏魯魯 | 0 | 0 | 0 | 0 | 不適用 |
| 阿爾克梅斯 | 0 | 4 | 4 | 0 | 2.50 |
Insider & Institutional Ownership
內部人與機構所有權
94.8% of Alkermes shares are held by institutional investors. 1.1% of ULURU shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Alkermes 94.8%的股份由機構投資者持有。烏魯魯1.1%的股份由公司內部人士持有。相比之下，Alkermes 4.8%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一隻股票有望實現長期增長。
Earnings & Valuation
收益與估值
This table compares ULURU and Alkermes' top-line revenue, earnings per share and valuation.
該表格比較了烏魯魯和阿爾克梅斯的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ULURU | N/A | N/A | N/A | N/A | N/A |
| Alkermes | $1.17 billion | 3.46 | -$48.17 million | ($0.78) | -31.67 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 烏魯魯 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
| 阿爾克梅斯 | 11.7億美元 | 3.46 | -4,817萬元 | ($0.78) | -31.67 |
ULURU has higher earnings, but lower revenue than Alkermes.
烏魯魯的收益比Alkermes高，但營收比Alkermes低。
Profitability
盈利能力
This table compares ULURU and Alkermes' net margins, return on equity and return on assets.
此表比較了Uluru和Alkermes的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| ULURU | N/A | N/A | N/A |
| Alkermes | -11.41% | -1.10% | -0.60% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 烏魯魯 | 不適用 | 不適用 | 不適用 |
| 阿爾克梅斯 | -11.41% | -1.10% | -0.60% |
Summary
摘要
Alkermes beats ULURU on 6 of the 9 factors compared between the two stocks.
阿爾克梅斯在兩隻股票比較的9個因素中有6個擊敗了烏魯魯。
About ULURU
關於烏魯魯
(Get Rating)
(獲取評級)
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.
烏魯魯公司是一家專業醫療技術公司，基於其在美國和國際上獲得專利的Nanoflex和OraDisc技術，研究、開發和銷售一系列傷口護理和粘合劑薄膜產品。該公司提供Altrazeal，這是一種變形粉末敷料，用於治療各種傷口，如部分深度燒傷、供體部位、手術和創傷傷口，以及慢性傷口，包括糖尿病足、靜脈腿和壓瘡。其產品還包括用於治療潰爛瘡的Aphthasol糊劑；用於治療潰爛瘡的OraDisc A；以及用於治療和管理口腔疼痛的OraDisc B。烏魯魯公司，總部設在德克薩斯州的艾迪森。
About Alkermes
關於阿爾克姆斯
(Get Rating)
(獲取評級)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc是一家生物製藥公司，研究、開發和商業化藥物產品，以滿足美國、愛爾蘭和國際上不同治療領域患者未得到滿足的醫療需求。其銷售的產品包括用於治療精神分裂症的肌肉注射混懸劑Aristada；用於治療酒精和防止阿片類藥物依賴的VIVITROL；用於治療精神分裂症和雙相I型障礙的Risperdal Consta；用於治療精神分裂症和分裂情感障礙的INVEGA SUSTENNA；用於治療精神分裂症和分裂情感障礙的XEPLION、INVEGA TRINZA和TREVICTA；以及用於治療成人復發形式的多發性硬化症的VUMERITY，包括臨牀孤立綜合徵、復發緩解和活躍的繼發性進行性疾病。該公司還在開發LYBALVI，一種用於治療成人精神分裂症和雙相I型障礙的口服非典型抗精神病藥物候選藥物；以及nemvaleukin alfa，一種工程融合蛋白，用於擴大腫瘤殺傷免疫細胞，避免免疫抑制細胞的激活。它主要與Janssen製藥公司、Janssen製藥公司和Janssen製藥國際公司簽訂了合作協議。Alkermes plc成立於1987年，總部設在愛爾蘭都柏林。
Receive News & Ratings for ULURU Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ULURU and related companies with MarketBeat.com's FREE daily email newsletter.
接受《烏魯魯日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Uluru和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。